Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3622926 | 0.93 | NPSR1 (0.46) | SCN9ACNR2NPSR1HSD17B14MEN1 | |
| Trifluoroacetic Acid SCHEMBL3617256 | 0.85 | CTSA (0.42) | HSD17B14CTSA | |
| Trifluoroacetic Acid SCHEMBL3617476 | 0.79 | IKBKB (0.42) | NPSR1MEN1KMT2A | |
| SCHEMBL3608803 | 0.71 | ALDH1A1 (0.41) | CNR2MEN1KMT2ACNR1 | |
| SCHEMBL1137226 | 0.70 | HSD17B14 (0.57) | SCN9AHSD17B14CTSA | |
| SCHEMBL30367705 | 0.70 | HSD17B14 (0.57) | SCN9AHSD17B14CTSA | |
| SCHEMBL16026874 | 0.69 | IKBKB (0.46) | MEN1KMT2A | |
| SCHEMBL28876906 | 0.68 | SCN9A (0.62) | SCN9AHSD17B14 | |
| Trifluoroacetic Acid SCHEMBL3620271 | 0.67 | HRH3 (0.49) | NPSR1 | |
| SCHEMBL3170205 | 0.67 | RAB9A (0.50) | NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304438-B2 | Heteroarylacrylamides and their use as pharmaceuticals | SANOFI (FR) | 2012-11-06 | — | — | US | disclosed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2099753-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-09-16 | — | — | EP | disclosed |
| EP-1939180-A1 | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074413-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | NOS3, PTGIS, NOS1 | SCN9A 3082/4885CNR2 686/4885NPSR1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.